Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells
We previously developed salinomycin (sali)-entrapped nanoparticles labeled with CD133 aptamers which could efficiently eliminate CD133+ osteosarcoma cancer stem cells (CSCs). However, sufficient evidences suggest that the simultaneous targeting both CSCs and cancer cells is pivotal in achieving pref...
Gespeichert in:
| Veröffentlicht in: | Nanomedicine 2018-10, Vol.14 (7), p.2115-2127 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2127 |
|---|---|
| container_issue | 7 |
| container_start_page | 2115 |
| container_title | Nanomedicine |
| container_volume | 14 |
| creator | Chen, Fangyi Zeng, Yibin Qi, Xiaoxia Chen, Yanchao Ge, Zhe Jiang, Zengxin Zhang, Xinchao Dong, Yinmei Chen, Huaiwen Yu, Zuochong |
| description | We previously developed salinomycin (sali)-entrapped nanoparticles labeled with CD133 aptamers which could efficiently eliminate CD133+ osteosarcoma cancer stem cells (CSCs). However, sufficient evidences suggest that the simultaneous targeting both CSCs and cancer cells is pivotal in achieving preferable cancer therapeutic efficacy, due to the spontaneous conversion between cancer cells and CSCs. We hereby constructed sali-entrapped lipid-polymer nanoparticles labeled with CD133 and EGFR aptamers (CESP) to target both osteosarcoma cells and CSCs. The cytotoxicity of CESP in osteosarcoma cells and CSCs was superior to that of single targeting or nontargeted sali-loaded nanoparticles. Administration of CESP in vivo showed the best efficacy in inhibiting tumor growth than other controls in osteosarcoma-bearing mice. Thus, CESP was demonstrated to be capable of efficiently targeting both osteosarcoma CSCs and cancer cells, and it represents an effective potential approach to treat osteosarcoma.
The mechanism of the superior targeting efficacy of CESP in osteosarcoma cells. [Display omitted] |
| doi_str_mv | 10.1016/j.nano.2018.05.015 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2055615338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1549963418301072</els_id><sourcerecordid>2055615338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-72cf1fb91789799cfe31ac95412d87670354d25ef04cfb9ca089185f763d152b3</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EoqXwAj1UPnJJ6j9xEktc0NKWSpWQUDlbjj0pXjlxsL1b7aPwtnW6pUdOHnl-36eZ-RA6p6SmhLaX23rWc6gZoX1NRE2oeINOqWhkJduGvX2teXOCPqS0JYR3hMj36ITJXvYN46fo772OD5DB4qS9m8N0MG7GFrzbQzzgR5d_46ub659YzxZvvlHOsV6yniAmPOhUdHanfeXdwwp4tzhbLcEfCoDX6RYdszMeEs4BD6G4hZQhJB1NmDQ24H169jZ6NkVTmtPx9yN6N2qf4NPLe4Z-XV_db75Xdz9ubjdf7yrDRZurjpmRjoOkXS87Kc0InGojRUOZ7bu2I1w0lgkYSWMKZjTpJe3F2LXcUsEGfoY-H32XGP7sIGU1ubROoGcIu6QYEaKlgvO-oOyImhhSijCqJbpJx4OiRK2RqK1al1ZrJIoIVSIpoosX_90wgX2V_MugAF-OAJQt9w6iSsZBuYZ1EUxWNrj_-T8Bih2e_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2055615338</pqid></control><display><type>article</type><title>Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Chen, Fangyi ; Zeng, Yibin ; Qi, Xiaoxia ; Chen, Yanchao ; Ge, Zhe ; Jiang, Zengxin ; Zhang, Xinchao ; Dong, Yinmei ; Chen, Huaiwen ; Yu, Zuochong</creator><creatorcontrib>Chen, Fangyi ; Zeng, Yibin ; Qi, Xiaoxia ; Chen, Yanchao ; Ge, Zhe ; Jiang, Zengxin ; Zhang, Xinchao ; Dong, Yinmei ; Chen, Huaiwen ; Yu, Zuochong</creatorcontrib><description>We previously developed salinomycin (sali)-entrapped nanoparticles labeled with CD133 aptamers which could efficiently eliminate CD133+ osteosarcoma cancer stem cells (CSCs). However, sufficient evidences suggest that the simultaneous targeting both CSCs and cancer cells is pivotal in achieving preferable cancer therapeutic efficacy, due to the spontaneous conversion between cancer cells and CSCs. We hereby constructed sali-entrapped lipid-polymer nanoparticles labeled with CD133 and EGFR aptamers (CESP) to target both osteosarcoma cells and CSCs. The cytotoxicity of CESP in osteosarcoma cells and CSCs was superior to that of single targeting or nontargeted sali-loaded nanoparticles. Administration of CESP in vivo showed the best efficacy in inhibiting tumor growth than other controls in osteosarcoma-bearing mice. Thus, CESP was demonstrated to be capable of efficiently targeting both osteosarcoma CSCs and cancer cells, and it represents an effective potential approach to treat osteosarcoma.
The mechanism of the superior targeting efficacy of CESP in osteosarcoma cells. [Display omitted]</description><identifier>ISSN: 1549-9634</identifier><identifier>EISSN: 1549-9642</identifier><identifier>DOI: 10.1016/j.nano.2018.05.015</identifier><identifier>PMID: 29898423</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>AC133 Antigen - chemistry ; Animals ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - pharmacology ; Apoptosis - drug effects ; Aptamers, Nucleotide - chemistry ; Bone Neoplasms - drug therapy ; Bone Neoplasms - metabolism ; Bone Neoplasms - pathology ; Cancer stem cells ; CD133 ; Cell Proliferation - drug effects ; Drug Delivery Systems ; Dual targeting ; EGFR ; ErbB Receptors - chemistry ; Female ; Humans ; Lipids - chemistry ; Mice ; Mice, Nude ; Nanoparticles - administration & dosage ; Nanoparticles - chemistry ; Neoplastic Stem Cells - drug effects ; Neoplastic Stem Cells - metabolism ; Neoplastic Stem Cells - pathology ; Osteosarcoma ; Osteosarcoma - drug therapy ; Osteosarcoma - metabolism ; Osteosarcoma - pathology ; Polymers - chemistry ; Pyrans - administration & dosage ; Pyrans - pharmacology ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays</subject><ispartof>Nanomedicine, 2018-10, Vol.14 (7), p.2115-2127</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-72cf1fb91789799cfe31ac95412d87670354d25ef04cfb9ca089185f763d152b3</citedby><cites>FETCH-LOGICAL-c356t-72cf1fb91789799cfe31ac95412d87670354d25ef04cfb9ca089185f763d152b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1549963418301072$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29898423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Fangyi</creatorcontrib><creatorcontrib>Zeng, Yibin</creatorcontrib><creatorcontrib>Qi, Xiaoxia</creatorcontrib><creatorcontrib>Chen, Yanchao</creatorcontrib><creatorcontrib>Ge, Zhe</creatorcontrib><creatorcontrib>Jiang, Zengxin</creatorcontrib><creatorcontrib>Zhang, Xinchao</creatorcontrib><creatorcontrib>Dong, Yinmei</creatorcontrib><creatorcontrib>Chen, Huaiwen</creatorcontrib><creatorcontrib>Yu, Zuochong</creatorcontrib><title>Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells</title><title>Nanomedicine</title><addtitle>Nanomedicine</addtitle><description>We previously developed salinomycin (sali)-entrapped nanoparticles labeled with CD133 aptamers which could efficiently eliminate CD133+ osteosarcoma cancer stem cells (CSCs). However, sufficient evidences suggest that the simultaneous targeting both CSCs and cancer cells is pivotal in achieving preferable cancer therapeutic efficacy, due to the spontaneous conversion between cancer cells and CSCs. We hereby constructed sali-entrapped lipid-polymer nanoparticles labeled with CD133 and EGFR aptamers (CESP) to target both osteosarcoma cells and CSCs. The cytotoxicity of CESP in osteosarcoma cells and CSCs was superior to that of single targeting or nontargeted sali-loaded nanoparticles. Administration of CESP in vivo showed the best efficacy in inhibiting tumor growth than other controls in osteosarcoma-bearing mice. Thus, CESP was demonstrated to be capable of efficiently targeting both osteosarcoma CSCs and cancer cells, and it represents an effective potential approach to treat osteosarcoma.
The mechanism of the superior targeting efficacy of CESP in osteosarcoma cells. [Display omitted]</description><subject>AC133 Antigen - chemistry</subject><subject>Animals</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Aptamers, Nucleotide - chemistry</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - metabolism</subject><subject>Bone Neoplasms - pathology</subject><subject>Cancer stem cells</subject><subject>CD133</subject><subject>Cell Proliferation - drug effects</subject><subject>Drug Delivery Systems</subject><subject>Dual targeting</subject><subject>EGFR</subject><subject>ErbB Receptors - chemistry</subject><subject>Female</subject><subject>Humans</subject><subject>Lipids - chemistry</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Nanoparticles - administration & dosage</subject><subject>Nanoparticles - chemistry</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Neoplastic Stem Cells - metabolism</subject><subject>Neoplastic Stem Cells - pathology</subject><subject>Osteosarcoma</subject><subject>Osteosarcoma - drug therapy</subject><subject>Osteosarcoma - metabolism</subject><subject>Osteosarcoma - pathology</subject><subject>Polymers - chemistry</subject><subject>Pyrans - administration & dosage</subject><subject>Pyrans - pharmacology</subject><subject>Tumor Cells, Cultured</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1549-9634</issn><issn>1549-9642</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxi0EoqXwAj1UPnJJ6j9xEktc0NKWSpWQUDlbjj0pXjlxsL1b7aPwtnW6pUdOHnl-36eZ-RA6p6SmhLaX23rWc6gZoX1NRE2oeINOqWhkJduGvX2teXOCPqS0JYR3hMj36ITJXvYN46fo772OD5DB4qS9m8N0MG7GFrzbQzzgR5d_46ub659YzxZvvlHOsV6yniAmPOhUdHanfeXdwwp4tzhbLcEfCoDX6RYdszMeEs4BD6G4hZQhJB1NmDQ24H169jZ6NkVTmtPx9yN6N2qf4NPLe4Z-XV_db75Xdz9ubjdf7yrDRZurjpmRjoOkXS87Kc0InGojRUOZ7bu2I1w0lgkYSWMKZjTpJe3F2LXcUsEGfoY-H32XGP7sIGU1ubROoGcIu6QYEaKlgvO-oOyImhhSijCqJbpJx4OiRK2RqK1al1ZrJIoIVSIpoosX_90wgX2V_MugAF-OAJQt9w6iSsZBuYZ1EUxWNrj_-T8Bih2e_g</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Chen, Fangyi</creator><creator>Zeng, Yibin</creator><creator>Qi, Xiaoxia</creator><creator>Chen, Yanchao</creator><creator>Ge, Zhe</creator><creator>Jiang, Zengxin</creator><creator>Zhang, Xinchao</creator><creator>Dong, Yinmei</creator><creator>Chen, Huaiwen</creator><creator>Yu, Zuochong</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201810</creationdate><title>Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells</title><author>Chen, Fangyi ; Zeng, Yibin ; Qi, Xiaoxia ; Chen, Yanchao ; Ge, Zhe ; Jiang, Zengxin ; Zhang, Xinchao ; Dong, Yinmei ; Chen, Huaiwen ; Yu, Zuochong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-72cf1fb91789799cfe31ac95412d87670354d25ef04cfb9ca089185f763d152b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>AC133 Antigen - chemistry</topic><topic>Animals</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Aptamers, Nucleotide - chemistry</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - metabolism</topic><topic>Bone Neoplasms - pathology</topic><topic>Cancer stem cells</topic><topic>CD133</topic><topic>Cell Proliferation - drug effects</topic><topic>Drug Delivery Systems</topic><topic>Dual targeting</topic><topic>EGFR</topic><topic>ErbB Receptors - chemistry</topic><topic>Female</topic><topic>Humans</topic><topic>Lipids - chemistry</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Nanoparticles - administration & dosage</topic><topic>Nanoparticles - chemistry</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Neoplastic Stem Cells - metabolism</topic><topic>Neoplastic Stem Cells - pathology</topic><topic>Osteosarcoma</topic><topic>Osteosarcoma - drug therapy</topic><topic>Osteosarcoma - metabolism</topic><topic>Osteosarcoma - pathology</topic><topic>Polymers - chemistry</topic><topic>Pyrans - administration & dosage</topic><topic>Pyrans - pharmacology</topic><topic>Tumor Cells, Cultured</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Fangyi</creatorcontrib><creatorcontrib>Zeng, Yibin</creatorcontrib><creatorcontrib>Qi, Xiaoxia</creatorcontrib><creatorcontrib>Chen, Yanchao</creatorcontrib><creatorcontrib>Ge, Zhe</creatorcontrib><creatorcontrib>Jiang, Zengxin</creatorcontrib><creatorcontrib>Zhang, Xinchao</creatorcontrib><creatorcontrib>Dong, Yinmei</creatorcontrib><creatorcontrib>Chen, Huaiwen</creatorcontrib><creatorcontrib>Yu, Zuochong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nanomedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Fangyi</au><au>Zeng, Yibin</au><au>Qi, Xiaoxia</au><au>Chen, Yanchao</au><au>Ge, Zhe</au><au>Jiang, Zengxin</au><au>Zhang, Xinchao</au><au>Dong, Yinmei</au><au>Chen, Huaiwen</au><au>Yu, Zuochong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells</atitle><jtitle>Nanomedicine</jtitle><addtitle>Nanomedicine</addtitle><date>2018-10</date><risdate>2018</risdate><volume>14</volume><issue>7</issue><spage>2115</spage><epage>2127</epage><pages>2115-2127</pages><issn>1549-9634</issn><eissn>1549-9642</eissn><abstract>We previously developed salinomycin (sali)-entrapped nanoparticles labeled with CD133 aptamers which could efficiently eliminate CD133+ osteosarcoma cancer stem cells (CSCs). However, sufficient evidences suggest that the simultaneous targeting both CSCs and cancer cells is pivotal in achieving preferable cancer therapeutic efficacy, due to the spontaneous conversion between cancer cells and CSCs. We hereby constructed sali-entrapped lipid-polymer nanoparticles labeled with CD133 and EGFR aptamers (CESP) to target both osteosarcoma cells and CSCs. The cytotoxicity of CESP in osteosarcoma cells and CSCs was superior to that of single targeting or nontargeted sali-loaded nanoparticles. Administration of CESP in vivo showed the best efficacy in inhibiting tumor growth than other controls in osteosarcoma-bearing mice. Thus, CESP was demonstrated to be capable of efficiently targeting both osteosarcoma CSCs and cancer cells, and it represents an effective potential approach to treat osteosarcoma.
The mechanism of the superior targeting efficacy of CESP in osteosarcoma cells. [Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29898423</pmid><doi>10.1016/j.nano.2018.05.015</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1549-9634 |
| ispartof | Nanomedicine, 2018-10, Vol.14 (7), p.2115-2127 |
| issn | 1549-9634 1549-9642 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2055615338 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | AC133 Antigen - chemistry Animals Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - pharmacology Apoptosis - drug effects Aptamers, Nucleotide - chemistry Bone Neoplasms - drug therapy Bone Neoplasms - metabolism Bone Neoplasms - pathology Cancer stem cells CD133 Cell Proliferation - drug effects Drug Delivery Systems Dual targeting EGFR ErbB Receptors - chemistry Female Humans Lipids - chemistry Mice Mice, Nude Nanoparticles - administration & dosage Nanoparticles - chemistry Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism Neoplastic Stem Cells - pathology Osteosarcoma Osteosarcoma - drug therapy Osteosarcoma - metabolism Osteosarcoma - pathology Polymers - chemistry Pyrans - administration & dosage Pyrans - pharmacology Tumor Cells, Cultured Xenograft Model Antitumor Assays |
| title | Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T21%3A06%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20salinomycin%20delivery%20with%20EGFR%20and%20CD133%20aptamers%20based%20dual-ligand%20lipid-polymer%20nanoparticles%20to%20both%20osteosarcoma%20cells%20and%20cancer%20stem%20cells&rft.jtitle=Nanomedicine&rft.au=Chen,%20Fangyi&rft.date=2018-10&rft.volume=14&rft.issue=7&rft.spage=2115&rft.epage=2127&rft.pages=2115-2127&rft.issn=1549-9634&rft.eissn=1549-9642&rft_id=info:doi/10.1016/j.nano.2018.05.015&rft_dat=%3Cproquest_cross%3E2055615338%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2055615338&rft_id=info:pmid/29898423&rft_els_id=S1549963418301072&rfr_iscdi=true |